Literature DB >> 10803521

Effects of the chemokine stromal cell-derived factor-1 on the migration and localization of precursor-B acute lymphoblastic leukemia cells within bone marrow stromal layers.

K F Bradstock1, V Makrynikola, A Bianchi, W Shen, J Hewson, D J Gottlieb.   

Abstract

Acute lymphoblastic leukemia (ALL) blasts undergo migration into layers of bone marrow fibroblasts (BMF) in vitro, utilizing the beta1 integrins VLA-4 and VL-5 as adhesion molecules. However, it has been unclear as to whether this is a selective process mediated by specific chemoattractant molecules, or simply a reflection of the highly motile nature of early B cell precursors. We further characterized this process using a transwell culture system, in which the two chambers were separated by an 8 microm diameter microporous membrane, through which leukemic cells could move. When a BMF layer was grown on the upper surface of the membrane there was an 84.1% reduction in transmigration of the human pre-B ALL cell line NALM-6 into the lower chamber, compared to control membrane with no BMF layer. Localization of leukemic cells under the BMF layer was confirmed ultrastructurally, suggesting the possibility that the migration of leukemic cells was directed by a chemotactic agent secreted by BMF. The involvement of the chemokine stromal cell-derived factor-1 (SDF-1) in this process was next investigated. BMF were shown to express m-RNA for SDF-1. Addition of SDF-1 at 100 ng/ml into the lower chamber increased transmigration of NALM-6 across the membrane by 2.2-fold, and also induced a 1.4- to 6.1-fold increase in movement of NALM-6 through a BMF layer into the lower chamber. The receptor for SDF-1, CXCR4, was demonstrated by flow cytometry on all 10 cases of precursor-B ALL analyzed, as well as on NALM-6, KM-3 and REH lines. An inhibitory antibody to CXCR4 was able to block the migration of NALM-6 cells into BMF monolayers grown on plastic by 51%, and in nine cases of ALL by 8-40%, as well as partially inhibit transmigration of leukemic cells through BMF layers along an SDF-1 concentration gradient. These results confirm that precursor-B ALL cells selectively localize within bone marrow stroma in vitro, and that this process is partially due to the stromal chemokine SDF-1 binding to its receptor CXCR4 on leukemic cells. SDF-1 may be important in influencing the localization of precursor-B ALL cells in marrow microenvironmental inches which regulate their survival and proliferation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10803521     DOI: 10.1038/sj.leu.2401729

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  23 in total

1.  Induction of the chemokine stromal-derived factor-1 following DNA damage improves human stem cell function.

Authors:  T Ponomaryov; A Peled; I Petit; R S Taichman; L Habler; J Sandbank; F Arenzana-Seisdedos; A Magerus; A Caruz; N Fujii; A Nagler; M Lahav; M Szyper-Kravitz; D Zipori; T Lapidot
Journal:  J Clin Invest       Date:  2000-12       Impact factor: 14.808

2.  Bone marrow mesenchymal stromal cells non-selectively protect chronic myeloid leukemia cells from imatinib-induced apoptosis via the CXCR4/CXCL12 axis.

Authors:  Fabrizio Vianello; Federica Villanova; Veronica Tisato; Stefania Lymperi; Ka-Kei Ho; Ana R Gomes; David Marin; Dominique Bonnet; Jane Apperley; Eric W-F Lam; Francesco Dazzi
Journal:  Haematologica       Date:  2010-02-23       Impact factor: 9.941

Review 3.  Therapeutic targeting of microenvironmental interactions in leukemia: mechanisms and approaches.

Authors:  Marina Konopleva; Yoko Tabe; Zhihong Zeng; Michael Andreeff
Journal:  Drug Resist Updat       Date:  2009-07-25       Impact factor: 18.500

4.  MLL-rearranged acute lymphoblastic leukaemia stem cell interactions with bone marrow stroma promote survival and therapeutic resistance that can be overcome with CXCR4 antagonism.

Authors:  Edward Allan R Sison; Rachel E Rau; Emily McIntyre; Li Li; Donald Small; Patrick Brown
Journal:  Br J Haematol       Date:  2013-01-07       Impact factor: 6.998

5.  Phase I study of the safety and pharmacokinetics of plerixafor in children undergoing a second allogeneic hematopoietic stem cell transplantation for relapsed or refractory leukemia.

Authors:  Ashok Srinivasan; John C Panetta; Shane J Cross; Asha Pillai; Brandon M Triplett; David R Shook; Mari H Dallas; Christine Hartford; Anusha Sunkara; Guolian Kang; Jeffrey Jacobsen; John Choi; Wing Leung
Journal:  Biol Blood Marrow Transplant       Date:  2014-04-23       Impact factor: 5.742

6.  Homing of cancer cells to the bone.

Authors:  Anjali Mishra; Yusuke Shiozawa; Kenneth J Pienta; Russell S Taichman
Journal:  Cancer Microenviron       Date:  2011-08-09

Review 7.  CXCL12/CXCR4 axis in the pathogenesis of acute lymphoblastic leukemia (ALL): a possible therapeutic target.

Authors:  Aparecida de Lourdes Perim; Marla Karine Amarante; Roberta Losi Guembarovski; Carlos Eduardo Coral de Oliveira; Maria Angelica Ehara Watanabe
Journal:  Cell Mol Life Sci       Date:  2015-01-09       Impact factor: 9.261

8.  PARC/CCL18 is a plasma CC chemokine with increased levels in childhood acute lymphoblastic leukemia.

Authors:  Sofie Struyf; Evemie Schutyser; Mieke Gouwy; Klara Gijsbers; Paul Proost; Yves Benoit; Ghislain Opdenakker; Jo Van Damme; Geneviève Laureys
Journal:  Am J Pathol       Date:  2003-11       Impact factor: 4.307

9.  Capture and printing of fixed stromal cell membranes for bioactive display on PDMS surfaces.

Authors:  Jungwoo Lee; Jennifer B Wang; Francesca Bersani; Biju Parekkadan
Journal:  Langmuir       Date:  2013-08-12       Impact factor: 3.882

10.  Total body irradiation is permissive for mesenchymal stem cell-mediated new bone formation following local transplantation.

Authors:  Samuel Herberg; Galina Kondrikova; Khaled A Hussein; Sudharsan Periyasamy-Thandavan; Maribeth H Johnson; Mohammed E Elsalanty; Xingming Shi; Mark W Hamrick; Carlos M Isales; William D Hill
Journal:  Tissue Eng Part A       Date:  2014-12       Impact factor: 3.845

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.